Trial Profile
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 in Cystic Fibrosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Lenabasum (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors Corbus Pharmaceuticals
- 08 Nov 2017 According to a Corbus Pharmaceuticals media release, data from this study was presented at the European Cystic Fibrosis Society ("ECFS") conference in June 2017 and was also recently presented at the North American Cystic Fibrosis Conference ("NACFC").
- 25 Sep 2017 According to a Corbus Pharmaceuticals media release, data will be presented at the 2017 North American Cystic Fibrosis Conference (NACFC).
- 09 May 2017 According to a Corbus Pharmaceuticals media release, results from this trial will be presented at the European Cystic Fibrosis (ECFS) conference in June 2017 and the North American Cystic Fibrosis Conference (NACFC) in November 2017.